Accuray Incorporated (NASDAQ:ARAY) insider Andrew J. Kirkpatrick sold 8,222 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $3.75, for a total transaction of $30,832.50. Following the completion of the transaction, the insider now owns 232,414 shares of the company’s stock, valued at approximately $871,552.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
ARAY stock opened at $3.81 on Monday. The stock has a market capitalization of $335.37 million, a PE ratio of -13.61 and a beta of 1.86. The stock’s 50-day moving average is $3.79. The company has a quick ratio of 1.03, a current ratio of 1.71 and a debt-to-equity ratio of 3.06. Accuray Incorporated has a 52 week low of $3.00 and a 52 week high of $5.40.
Accuray (NASDAQ:ARAY) last released its earnings results on Tuesday, April 23rd. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $103.22 million during the quarter, compared to analysts’ expectations of $104.02 million. Accuray had a negative net margin of 3.85% and a negative return on equity of 25.91%. On average, equities research analysts expect that Accuray Incorporated will post -0.16 earnings per share for the current year.
A number of brokerages have weighed in on ARAY. BidaskClub upgraded shares of Accuray from a “sell” rating to a “hold” rating in a research report on Wednesday, April 24th. BTIG Research reiterated a “hold” rating on shares of Accuray in a research report on Wednesday, April 24th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $5.13.
Hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. increased its stake in shares of Accuray by 46.7% during the fourth quarter. Macquarie Group Ltd. now owns 7,810 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,487 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Accuray during the first quarter worth about $49,000. Amalgamated Bank purchased a new stake in shares of Accuray during the fourth quarter worth about $43,000. Stone Ridge Asset Management LLC purchased a new stake in shares of Accuray during the fourth quarter worth about $51,000. Finally, BNP Paribas Arbitrage SA increased its stake in shares of Accuray by 1,515.8% during the first quarter. BNP Paribas Arbitrage SA now owns 19,099 shares of the medical equipment provider’s stock worth $91,000 after purchasing an additional 17,917 shares in the last quarter. 81.24% of the stock is owned by institutional investors and hedge funds.
Accuray Company Profile
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.